Benzinga's Top Pre-Market Losers
Amicus Therapeutics (NASDAQ: FOLD) shares dropped 46.97% to $3.06 in pre-market trading. Amicus Therapeutics and GlaxoSmithKline plc (NYSE: GSK) today announced the 6-month primary treatment period results from the first Phase 3 global registration study.
Allscripts Healthcare Solutions (NASDAQ: MDRX) shares fell 16.48% to $8.92 in the pre-market trading. Allscripts appointed Paul Black as its CEO.
Accenture plc (NYSE: ACN) dipped 5.21% to $66.73 in the pre-market session. Accenture projects Q2 revenue of $6.9 billion of $7.15 billion, versus analysts' estimates of $7.14 billion.
Bed Bath & Beyond (NASDAQ: BBBY) dipped 4.86% to $57.35 in the pre-market session. Bed Bath & Beyond issued downbeat fourth-quarter earnings forecast. The company's board also authorized a new $2.5 billion share repurchase program.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.